To investigate mechanisms that enable ER+/HER2− breast cancer CTCs to escape from ERα inhibition, we used CTCs from an ER+/HER2− breast cancer patient who initially responded but later progressed under endocrine treatment. The gene discussed is ESR1; the disease is breast carcinoma.